Empowered Funds LLC Reduces Stake in Humana Inc. (NYSE:HUM)

Empowered Funds LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 74.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,836 shares of the insurance provider’s stock after selling 11,078 shares during the period. Empowered Funds LLC’s holdings in Humana were worth $973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. State Street Corp raised its position in Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC boosted its holdings in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Pzena Investment Management LLC grew its position in Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after acquiring an additional 187,903 shares during the last quarter. Ontario Teachers Pension Plan Board increased its stake in Humana by 6.5% in the third quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock worth $371,705,000 after purchasing an additional 71,910 shares during the period. Finally, Sanders Capital LLC lifted its position in shares of Humana by 1.0% during the third quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock worth $370,060,000 after purchasing an additional 11,923 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Trading Up 0.3 %

Humana stock opened at $253.61 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market cap of $30.54 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The stock has a 50-day moving average of $271.27 and a two-hundred day moving average of $292.96. Humana Inc. has a one year low of $213.31 and a one year high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, research analysts anticipate that Humana Inc. will post 16.11 EPS for the current fiscal year.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. TD Cowen lifted their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Barclays increased their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, Piper Sandler lifted their target price on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $293.05.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.